Drug Trial Radar · NCT07308132
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
340
Planned (sponsor's estimate)
Start
Jan 20, 2026
Primary completion
Aug 31, 2028
Study completion Oct 31, 2029
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Dec 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the putative recommended Phase 2 doses (RP2Ds) and optimal dose schedule(s) for JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) and for JNJ-95566692 with or without JNJ-87801493 with various standard of care (SOC) regimens (Arms C-G) in Part 1: Dose Escalation part of the study. Part 2: Dose Expansion part of the study will further characterize the safety.
Conditions
- Lymphoma, Non-Hodgkin
Interventions
JNJ-95566692Drug
JNJ-95566692 will be administered subcutaneously.
JNJ-87801493Drug
JNJ-87801493 will be administered subcutaneously.
loncastuximab tesirineDrug
Loncastuximab tesirine will be administered intervenously.
LenalidomideDrug
Lenalidomide will be administered orally.
RituximabDrug
Rituximab will be administered intravenously and may be administered subcutaneously after the first administration.
GemcitabineDrug
Gemcitabine will be administered intravenously.
OxaliplatinDrug
Oxaliplatin will be administered intravenously.
CyclophosphamideDrug
Cyclophosphamide will be administered intravenously.
DoxorubicinDrug
Doxorubicin will be administered intravenously.
VincristineDrug
Vincristine will be administered intravenously.
PrednisoneDrug
Prednisone will be administered orally.
Polatuzumab vedotinDrug
Polatuzumab vedotin will be administered intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 and 2: Number of Participants with Adverse Events (AEs) And Serious Adverse Events (SAEs) by SeverityTime frame: Approximately 2 years and 8 months
- Part 1: Number of Participants with Dose Limiting Toxicity (DLTs)Time frame: Approximately 2 years and 8 months
Locations
19 sites in 5 countries. Site status is shown where the registry gives one.
Monash Medical Centre
Clayton, Australia · Recruiting
Peter MacCallum Cancer Centre
Melbourne, Australia · Recruiting
Macquarie University Hospital
North Ryde, Australia · Recruiting
Scientia Clinical Research
Randwick, Australia · Recruiting
UZ Antwerpen
Edegem, Belgium · Recruiting
Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
Liège, Belgium · Recruiting
Hopital Claude Huriez
Lille, France · Recruiting
CHU Pitie Salpetriere
Paris, France · Recruiting
CHU Lyon Sud
Pierre-Bénite, France · Recruiting
Institut Universitaire du Cancer Toulouse Oncopole
Toulouse, France · Recruiting
Hosp Univ Vall D Hebron
Barcelona, Spain · Recruiting
Hosp. Clinic de Barcelona
Barcelona, Spain · Recruiting
Hosp Univ Fund Jimenez Diaz
Madrid, Spain · Recruiting
Hosp. Univ. 12 de Octubre
Madrid, Spain · Recruiting
Hosp Univ Hm Sanchinarro
Madrid, Spain · Recruiting
SBU Ankara Dr. Abdurrahman Yurtaslan Onkoloji Egitim ve Arastirma Hastanesi Faz 1 Merkezi
Ankara, Turkey (Türkiye) · Recruiting
Ankara Universitesi Hastaneleri Tibbi Farmakoloji Anabilim Dali Faz 1 Klinik Arastirma Merkezi
Ankara, Turkey (Türkiye) · Recruiting
Memorial Antalya Hastanesi Faz 1 Klinik Arastirma Merkezi
Antalya, Turkey (Türkiye) · Recruiting
Koc Universitesi Hastanesi Faz 1 Klinik Arastirma Merkezi
Istanbul, Turkey (Türkiye) · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.